Jun 15, 2022 / 05:00PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good morning everyone, thanks for joining us. Really pleased to have the Adaptive team here with us. We have Chad Robins, CEO of the company; and Tycho Peterson, CFO of the company. With that, Chad, can I open it to you for opening comments here?
Chad M. Robins - Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman
Sure. So we founded the company in 2009 with my brother, Harlan, [spun-off] Fred Hutchinson Cancer Research Center based on the premise that if we could learn to kind of read and translate how the adaptive immune system naturally both detects and treat disease that we could create clinical products both in diagnostics for earlier detection of disease, and we could harness the power of the immune system as a targeting molecule for therapeutics and drug discovery. And so that's what we've done.
We've -- the business is comprised of really 2 segments. One is in MRD or minimal residual disease. What's different about our MRD is specifically focused on
Adaptive Biotechnologies Corp at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers